Correction to: NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699 (Oncogene, (2012), 31, 2, (251-264), 10.1038/onc.2011.229);NF-B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699

Oncogene

Volumn 31, Issue 2, 2012, Pages 251-264

  Hunter, J E ^a   Willmore, E ^a   Irving, J A E ^a   Hostomsky, Z ^b   Veuger, S J ^a   Durkacz, B W ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

AG 014699; NF kB; PAR; PARP 1; radio sensitization

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; RUCAPARIB; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; ENZYME INHIBITOR; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADP RIBOSE)POLYMERASE 1, MOUSE; POLY(ADP-RIBOSE)POLYMERASE-1, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; EMBRYO; GENETIC TRANSCRIPTION; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN FUNCTION; RADIOSENSITIZATION; SINGLE STRANDED DNA BREAK; ANIMAL; CELL LINE; DRUG ANTAGONISM; GENETICS; INFRARED RADIATION; METABOLISM; RADIATION DOSE;

ANIMALS; CELL LINE; ENZYME INHIBITORS; INDOLES; INFRARED RAYS; MICE; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; RADIATION TOLERANCE; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855798998     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-022-02524-2     Document Type: Erratum

References (57)

1. Althaus FR, Hofferer L, Kleczkowska HE, Malanga M, Naegeli H, Panzeter PL et al. (1994). Histone shuttling by poly ADPribosylation. Mol Cell Biochem 138: 53-59.
2. Barkett M, Gilmore T. (1999). Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18: 6910-6924.
3. Basseres DS, Baldwin AS. (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830. (Pubitemid 44657854)
4. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al. (2004). NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137-10142. (Pubitemid 38891208)
5. Bonicalzi ME, Haince JF, Droit A, Poirier GG. (2005). Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when? Cell Mol Life Sci 62: 739-750. (Pubitemid 40655624)
6. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. (1991). Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 88: 691-695.
7. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE et al. (1999). Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 274: 17599-17604.
8. Burger PC, Vogel FS, Green SB, Strike TA. (1985). Glioblsstoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications. Cancer 56: 1106-1111. (Pubitemid 15003495)
9. Chang WJ, Alvarez-Gonzalez R. (2001). The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J Biol Chem 276: 47664-47670.
10. Chariot A. (2009). The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 19: 404-413.
11. Clevers H. (2004). At the crossroads of inflammation and cancer. Cell 118: 671-674. (Pubitemid 39221727)
12. Criollo A, Senovilla L, Authier H, Chiara Maiuri M, Morselli E, Vitale I et al. (2010). The IKK complex contributes to the induction of autophagy. EMBO J 29: 619-631.
13. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA. (2003). Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 22: 5813-5827. (Pubitemid 37176702)
14. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ et al. (2009). Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 15: 1241-1249.
15. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S et al. (2010). Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103: 334-346.
16. Drew Y, Plummer R. (2009). PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 12: 153-156.
17. Durkacz BW, Omidiji O, Gray DA, Shall S. (1980). (ADP-ribose) participates in DNA excision repair. Nature 283: 593-596. (Pubitemid 10136042)
18. Ghosh G, Huang DB, Huxford T. (1999). Structural insights into NF-kB/IkB signaling. Gene Ther Mol Biol 4: 75-82.
19. Ghosh S, Karin M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl): S81-S96.
20. Gilmore TD, Herscovitch M. (2006). Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25: 6887-6899. (Pubitemid 44657858)
21. Grossman M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S. (1999). The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci USA 96: 11848-11853. (Pubitemid 29502821)
22. Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO. (2001). The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J Biol Chem 276: 45588-45597.
23. Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H et al. (2005). Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaBdependent transcription. J Biol Chem 280: 40450-40464. (Pubitemid 41780532)
24. Hassa PO, Hottiger MO. (1999). A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem 380: 953-959. (Pubitemid 29412755)
25. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML et al. (2008a). The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111: 4681-4689.
26. Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C et al. (2008b). The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res 14: 8102-8111.
27. Hewamana S, Lin TT, Rowntree C, Karunanithi K, Pratt G, Hills R et al. (2009). Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 27: 763-769.
28. Jackson A, Linsley P. (2004). Noise amidst the silence: off target effects of siRNAs? Trends Genet 20: 521-524. (Pubitemid 39314555)
29. Jung M, Dritschilo A. (2001). NF-kappa B signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 11: 346-351. (Pubitemid 32959669)
30. Kanzawa T, Ito H, Kondo Y, Kondo S. (2003). Current and future gene therapy for malignant gliomas. J Biomed Biotechnol 2003: 25-34. (Pubitemid 36828272)
31. Kauppinen TM, Swanson RA. (2005). Poly(ADP-ribose); polymerase-1 promotes microgial activation, proliferation and matrix metalloproteinase-9 mediated neuron death. J Immunol 174: 2288-2296. (Pubitemid 40223977)
32. Kraus WL, Lis JT. (2003). PARP goes transcription. Cell 113: 677-683. (Pubitemid 36724932)
33. Martin-Oliva D, Aguliar-Quesada R, O'valle F, Munoz-Gamez JA, Martinez-Romero R, Garcia Del-Moral R et al. (2006). Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 66: 5744-5756. (Pubitemid 43927128)
34. Mulligan EA, Hunter JE, Baird AEG, Elliott SL, Summerfield GP, Hamlen K et al. (2010). Relationships between aberrant activity of the NF-kB subunits and outcome in chronic lymphocytic leukaemia: the dual role of DNA damage sensor kinases. Blood 116: 1477.
35. Ogorek B, Bryant PE. (1985). Repair of DNA single-strand breaks in X-irradiated yeast. II. Kinetics of repair as measured by the DNAunwinding method. Mutat Res 146: 63-70. (Pubitemid 15051196)
36. Oliver FJ, Menissier de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S et al. (1999). Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADPribose) polymerase-1 deficient mice. EMBO J 18: 4446-4454. (Pubitemid 29391254)
37. Prasad S, Ravindran J, Aggarwal B. (2009). NF-kB and cancer: how intimate is this relationship. Mol Cell Biochem 336: 25-37.
38. Plummer ER,Middleton MR, Jones C, Olsen A, Hickson I, McHugh P et al. (2005a). Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 11: 3402-3409. (Pubitemid 40627893)
39. Plummer ER, Jones C, Middleton MR, Wilson R, Evans J, Olsen A et al. (2008). Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14: 7917-7923.
40. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R et al. (2006). First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignantmelanoma (MM). J Clin Oncol 24No. 18S, Part I: 8013.
41. Plummer R, Middleton M, Wilson R, Jones C, Evans J, Robson L et al. (2005b). First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J Clin Oncol 23No.16S, Part I: 3065.
42. Russo SM, Tepper JE, Baldwin Jr AS, Lui R, Adams J, Elliott P et al. (2001). Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183-193.
43. Sahijdak WM, Yang CR, Zuckerman JS, Meyers M, Boothman DA. (1994). Alterations in transcription factor binding in radioresistant human melanoma cells after ionizing radiation. Radiat Res 138: S47-S51. (Pubitemid 24116641)
44. Slama JT, Aboul-Ela N, Goli DM, Cheesman BV, Simmons AM, Jacobson MK. (1995). Specific inhibition of poly(ADP-ribose) glycohydrolase by adenosine diphosphate (hydroxymethyl)pyrrolidinediol. J Med Chem 38: 389-393.
45. Smith S. (2001). The world according to PARP. Trends Biochem Sci 26: 174-179. (Pubitemid 32197577)
46. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Schreiderit C. (2009). A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell 36: 365-378.
47. Trucco C, Javier Oliver F, de Murcia G, Menissier de Murcia J. (1998). DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acid Res 26: 2644-2649. (Pubitemid 28297377)
48. Tschaharganeh D, Ehemann V, Nussbaum T, Schrimacher P, Breuhahn K. (2007). Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathol Oncol Res 13: 84-90. (Pubitemid 47204729)
49. Turco MC, Romano MF, Petrella A, Bisgoni R, Tassone P, Ventuna S. (2004). NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 18: 11-17. (Pubitemid 38159433)
50. Ueda K, Hayaishi O. (1985). ADP-RIBOSYLATION Ann. Rev Biochem 54: 73-100.
51. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. (2003). Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63: 6008-6015. (Pubitemid 37187504)
52. Veuger SJ, Hunter JE, Durkacz BW. (2009). Ionizing radiationinduced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene 28: 832-842.
53. Wang CY, Mayo MW, Baldwin Jr AS. (1996). TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787. (Pubitemid 26398259)
54. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683.
55. Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. (2004). Analysis of the activation status of Akt, NFkappaB and Stat3 in human diffuse gliomas. Lab Invest 84: 941-951. (Pubitemid 39025029)
56. Wu JT, Kral JG. (2005). The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 123: 158-169. (Pubitemid 40094658)
57. Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ. (2009). Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer I 101: 256-262.